Pharma Mar (XMAD:PHM) Debt-to-Equity : 0.21 (As of Mar. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Pharma Mar Debt-to-Equity?

Pharma Mar's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €12.8 Mil. Pharma Mar's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €27.5 Mil. Pharma Mar's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €192.7 Mil. Pharma Mar's debt to equity for the quarter that ended in Mar. 2024 was 0.21.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Pharma Mar's Debt-to-Equity or its related term are showing as below:

XMAD:PHM' s Debt-to-Equity Range Over the Past 10 Years
Min: -16.87 Med: 1.25 Max: 722.01
Current: 0.21

During the past 13 years, the highest Debt-to-Equity Ratio of Pharma Mar was 722.01. The lowest was -16.87. And the median was 1.25.

XMAD:PHM's Debt-to-Equity is ranked worse than
57.28% of 1065 companies
in the Biotechnology industry
Industry Median: 0.14 vs XMAD:PHM: 0.21

Pharma Mar Debt-to-Equity Historical Data

The historical data trend for Pharma Mar's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Mar Debt-to-Equity Chart

Pharma Mar Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

7.57

0.55

0.28

0.19

0.23

Pharma Mar Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.20	0.21	0.21	0.23	0.21

Competitive Comparison of Pharma Mar's Debt-to-Equity

For the Biotechnology subindustry, Pharma Mar's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharma Mar's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Mar's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Pharma Mar's Debt-to-Equity falls into.

Pharma Mar Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Pharma Mar's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(14.805	+	28.864)	/	193.438
	=	0.23

Pharma Mar's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(12.794	+	27.466)	/	192.674
	=	0.21

Pharma Mar (XMAD:PHM) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Pharma Mar Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Pharma Mar's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharma Mar (XMAD:PHM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Mar SA (XMAD:PHM) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

PHMMF:USA PHMe:UK 0RC6:UK

Address

Avenida de los Reyes, 1, Poligono Industrial La Mina-norte, Colmenar Viejo, Madrid, ESP, 28770

Website

http://www.pharmamar.com

Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and market insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology, Diagnostics, Consumer chemicals, and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.